504292324 03/27/2017

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4339005

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
JUERGEN SIEKMANN	08/12/2011
STEFAN HAIDER	08/12/2011
HANSPETER ROTTENSTEINER	08/16/2011
ANDREAS IVENS	08/13/2011
PETER TURECEK	08/16/2011

RECEIVING PARTY DATA

Name:	BAXTER INTERNATIONAL INC.
Street Address:	ONE BAXTER PARKWAY
City:	DEERFIELD
State/Country:	ILLINOIS
Postal Code:	60015
Name:	BAXTER HEALTHCARE SA
	B, W. E. H. I.E. K.
Street Address:	THURGAUERSTRASSE 130
Street Address:	THURGAUERSTRASSE 130

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	15281616

CORRESPONDENCE DATA

Fax Number: (415)442-1001

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (415) 442-1000

linda.lim@morganlewis.com Email:

Correspondent Name: JEFFRY S. MANN

ONE MARKET, SPEAR STREET TOWER Address Line 1:

Address Line 2: MORGAN, LEWIS & BOCKIUS LLP Address Line 4: SAN FRANCISCO, CALIFORNIA 94105

ATTORNEY DOCKET NUMBER:	008073-5124-US05
NAME OF SUBMITTER:	LINDA LIM
SIGNATURE:	/Linda Lim/
DATE SIGNED:	03/27/2017
Total Attachments: 4 source=008073_5124_US05_Assignment_Inventors#page1.tif	

source=008073_5124_US05_Assignment_Inventors#page1.tif source=008073_5124_US05_Assignment_Inventors#page2.tif source=008073_5124_US05_Assignment_Inventors#page3.tif source=008073_5124_US05_Assignment_Inventors#page4.tif





Serial No. 13/194,038 Filed: July 29, 2011 Attorney Docket No. 31315/46384

For good and valuable considerations, the receipt and sufficiency whereof are hereby acknowledged, we hereby assign to **BAXTER INTERNATIONAL INC.**, a corporation of Delaware, having a principal place of business at Deerfield, Illinois, its successors, legal representatives and assigns, and to **BAXTER HEALTHCARE S.A.**, a corporation of Switzerland, having a principal place of business at Glattpark (Opfikon), Switzerland, its successors, legal representatives and assigns (hereinafter jointly referred to as "assignee") the entire right, title and interest throughout the world, to the extent not previously assigned to assignee, in our invention or improvements in

NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE

and, effective as of the date of filing, in the above listed application(s) for Letters Patent therefor, executed by each of us individually, and any and all other patent applications in any and all countries which have been or may hereafter be filed, either solely or jointly with others, on said invention or improvements, and in any and all Letters Patent of any country which may be obtained on any of the said applications, and in any reissue or extension thereof and any applications that claim priority thereto, including any regional and national stage applications.

We hereby authorize and request the patent offices of all countries to issue to the said assignee all patents that may issue on said invention or improvements. We hereby authorize and request the attorneys of record in said application to insert in this assignment the date and serial number and docket number of said applications when officially known.

We warrant ourselves to be the owners of the interest herein assigned and to have the right to make this assignment; and further warrant that there are no outstanding prior assignments, licenses, or other rights to any person or entity other than the assignee in the interest herein assigned.

For said considerations we hereby agree, upon the request and at the expense of said assignee, its successors, legal representatives and assigns, to execute any and all divisional, continuation, and renewal applications for said invention or improvements, and any necessary oath or supplemental oath or affidavit relating thereto, and any application for the reissue or extension of any Letters Patent that may be granted upon said application, including any regional and national stage applications that claim priority thereto, that said assignee, its successors, legal representatives and assigns may deem necessary or expedient, and for the said considerations we further agree, upon the request of said assignee, its successors, legal representatives and assigns, in the event of said application or any continuation or division thereof, or Letters Patent issued thereon, or any reissue or application for the reissue thereof becoming involved in interference, to cooperate to the best of our ability with said assignee, its successors, legal representatives and assigns in the matters of preparing and executing the preliminary statement and giving and producing evidence in support thereof.

We further agree to perform, upon such request, any and all affirmative acts, including but not limited to execution of any and all documents deemed necessary or expedient by the said assignee or its successors, legal representatives or assigns, to obtain Letters Patent, and vest all rights therein hereby conveyed in the said assignee, its successors, legal representatives and assigns whereby said Letters Patent will be held and enjoyed by the said sassignee, its successors, legal representatives and assigns to the end of the term for which said Letters Patent may be granted as fully and entirely as the same would have been held and enjoyed by us if this assignment and sale had not been made, and for the said considerations we hereby also assign to said assignee, its successors, legal representatives and assigns the entire right, title and interest in said invention or improvements for any and all foreign countries and the right of priority for patent and utility model applications in all countries arising under any applicable international convention for the protection of industrial property and/or any internal priority legislation of such countries, and we further agree upon the request of said assignee, its successors, legal representatives and assigns to execute any and all documents that shall be required to be executed in connection with any and all applications for foreign Letters Patent therefor, including the prosecution thereof, and to execute any and all documents necessary to invest title in said foreign applications and patents in said assignee.

WITNESS our hand and seal.

90775_1

Serial No. 13/194,038

Filed: July 29, 2011

Attorney Docket No. 31315/46384

NUCLEOPHILIC CATALYSTS I	FOR OXIME LINKAGE
Inventor Name: SIEKMANN, Juergen	Inventor Name: HAIDER, Stefan
Date August 12, 2011	Date August 12, 2011
Signature J. Let	Signature Kon Karia
Witness Name SCHEINECKER, Richard	Witness Name ScHEINECKER, Richard
Date August 12, 2011	Date August 12, 2011
Signature R. Skillielh	Signature R Schille
Inventor Name: ROTTENSTEINER, Hanspeter	Inventor Name: IVENS, Andreas
Date August 16, 2011	Date
Signature Mes we Malla Man	Signature
Witness Name GRUBER, EVELINE	Witness Name
Date August 16, 2011	Date
Signature C Pull	Signature
\triangle	



Signature Sheet (Joint Inventors)

Serial No. 13/194,038

Filed: July 29, 2011

Attorney Docket No. 31315/46384

NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE

Inventor Name: SIEKMANN, Juergen	Inventor Name: HAIDER, Stefan
Date	Date
Signature	Signature
Witness Name	Witness Name
Date	Date
Signature	Signature
Inventor Name ROTTENSTEINER, Hanspeter	Inventor Name: IVENS, Andreas
Date	Date 177 Avy Codd
Signature	Signature <u>Andreas Similas</u>
Witness Name	witness Name <u>Dagway</u> Mate
Date	Date
Signature	ON Wah

90775_1

Baxter

Supplemental Signature Sheet (Joint Inventors)

Serial No. 13/194,038 Filed: July 29, 2011 Attorney Docket No. 31315/46384

	•	
NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE		
Inventor Name: TURECEK, Peter	Inventor Name: ZOECHLING, Oliver	
Date 16.08.011	Date August 12, 2011	
Signature	Signature Signature	
Witness Name Sabine Mande	Witness Name SCHEINECKER, Richard	
Date August 16 2011	Date August 12, 2011	
Signature Lucial Pulia	Signature R. Shuul	

90775_1

RECORDED: 03/27/2017